Rare diseases

Partner Content

$Banner for Media partners {460x250px}_3rd Antibody Bispecifics$

Partner Content

3rd Annual Antibody Summit: Bispecifics & Multispecifics

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria.

Partner Content

$Banner for Media partners {460x250px}_4th Antibody Drug Conjugates$

Partner Content

4th Annual Antibody Drug Conjugates (ADC) Summit: From Targe...

We are pleased to invite you to the 4th Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 15-16, 2019 in Vienna, Austria.

News

AZ's Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.

News

Alexion signs R&D deals with two Nordic biotechs

Alexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs.

News

Vertex CEO hints at 'new ideas' to bring Orkambi to UK patie...

Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England.

News

Akcea/Ionis' rare disease drug Waylivra set for EU market af...

European regulators have recommended a licence for Akcea and Ionis’ ultra-rare disease drug Waylivra, a therapy that the FDA rejected for the US market last year.

3rd Annual Antibody Summit: Bispecifics & Multispecifics

4th Annual Antibody Drug Conjugates (ADC) Summit: From Targe...

AZ's Fasenra also works in rare organ damage diseases

Alexion signs R&D deals with two Nordic biotechs

Vertex CEO hints at 'new ideas' to bring Orkambi to UK patie...

Akcea/Ionis' rare disease drug Waylivra set for EU market af...

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

Rare diseases

Editor's Picks